KINAXO Enters Agreement with Bristol-Myers Squibb Company

KINAXO Enters Agreement with Bristol-Myers Squibb Company
Monday, 11 October 2010 11:00 (UTC + 2) 


Martinsried, Germany, October 11, 2010 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that Bristol-Myers Squibb Company (NYSE:BMY) has chosen KINAXO to support several of its drug discovery programs. Under the terms of the agreement, KINAXO will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at Bristol-Myers Squibb to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.

 

Dr Jutta Fritz, Head of Business Development at KINAXO commented: "We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world. We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States."

 

 

About KINAXO - www.kinaxo.com

KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. KINAXO's technology platform offers solutions for drug mode-of-action analysis, cellular target profiling, target deconvolution, drug repositioning and biomarker discovery. KINAXO maintains several collaborations with global pharmaceutical companies, such as Johnson & Johnson, Daiichi-Sankyo, Bayer, Roche and Boehringer Ingelheim. For more information, please visit http://www.kinaxo.com/.

 

Contact:

Dr. Jutta Fritz, MBA,
Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
82152 Martinsried
Email: [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Phone +49 89 4613363-22
http://www.kinaxo.com/

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.